Baidu
map

AIDS:HIV患者CD4细胞计数与缺血性卒中风险有关

2014-06-26 MedSci MedSci原创

一项为期15年的研究结果显示,HIV阳性的个体缺血性卒中的风险增高40%,但若此类个体CD4细胞计数增高,则相应风险与HIV阴性个体相似。 相关研究最近发表于国际AIDS学会官方杂志AIDS上。这项研究由1996年开始至2011年结束,涉及仅2.5万HIV阳性个体。缺血性卒中的发生是由于血管内斑块形成所致,可导致血管狭窄或堵塞,阻断脑部的血液和氧气供应。CD4细胞计数

一项为期15年的研究结果显示,HIV阳性的个体缺血性卒中的风险增高40%,但若此类个体CD4细胞计数增高,则相应风险与HIV阴性个体相似。

相关研究最近发表于国际AIDS学会官方杂志AIDS上。这项研究由1996年开始至2011年结束,涉及仅2.5万HIV阳性个体。缺血性卒中的发生是由于血管内斑块形成所致,可导致血管狭窄或堵塞,阻断脑部的血液和氧气供应。CD4细胞计数低于500提示对抗感染和炎症反应的白细胞数量较少,是免疫系统功能低下的标志。

这项研究涉及到两个队列,为1996-2011 (KPNC) or 2000-2011 (KPSC),分别进行观察。研究者采用Poisson模型观察HIV感染者缺血性卒中事件发生率,进一步总计、按CD4细胞计数和HIV的RNA copy进行分层分析。结果发现,在24768位HIV阳性和匹配的257600位HIV阴性的个体,每10万人年发生卒中事件在HIV阳性组为125 (n=151 events),在HIV阴性组为74 (n=1128 events),两者发生风险比为1.4 (95%CI: 1.2-1.7)。比较HIV阴性群体,在HIV阳性群体中,CD4细胞数量大于500/ul (rate ratio:1.0, 95%CI:0.8-1.4) ,而CD4小于500/ul中(rate ratio: 1.1, 95%CI:0.9-1.4),没有风险增加。在HIV阳性个体中,校正HIV RNA和nadir CD4后,CD4细胞计数低于200/ul,卒中风险明显增加(RR:2.5, 95%CI:1.3-4.6)

这项研究发现,近期CD4细胞计数是最强的HIV特异性危险因子,这表示免疫缺陷可影响缺血性卒中的发生风险。而且值得注意的是,近期CD4细胞计数≥500的HIV阳性个体,缺血性卒中的发生风险并未高于HIV阴性个体。但是CD4低于200时,风险明显增加。

如果免疫缺陷和缺血性卒中风险间存在因果关系,那么早期、持续进行抗逆转录病毒治疗以维持免疫功能,并联合其他卒中危险因素的缓解,或可使HIV阳性个体的缺血性卒中风险降至与一般人群相似的水平。

近期有观点认为应减少或终止对进行病毒抑制治疗的HIV阳性个体进行CD4水平监测。本项研究提示,维持免疫功能或许能预防缺血性卒中的发生,CD4细胞计数或许不仅仅可用于HIV病情的监测。

原始出处:

Marcus JL, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, Klein DB, Quesenberry CP Jr, Towner WJ, Silverberg MJ.HIV infection and incidence of ischemic stroke.AIDS. 2014 Jun 17.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2015-05-02 qidongfanjian
  3. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2015-05-05 wjywjy
  7. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1805992, encodeId=f62318059929b, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Nov 07 02:06:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864206, encodeId=4d3d18642063b, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat May 02 10:06:00 CST 2015, time=2015-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003339, encodeId=1e0120033392e, content=<a href='/topic/show?id=5012890397' target=_blank style='color:#2F92EE;'>#HIV患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8903, encryptionId=5012890397, topicName=HIV患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Mar 02 01:06:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892618, encodeId=370e18926186d, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue Dec 16 02:06:00 CST 2014, time=2014-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068341, encodeId=2c73206834120, content=<a href='/topic/show?id=d411434487' target=_blank style='color:#2F92EE;'>#CD4细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4344, encryptionId=d411434487, topicName=CD4细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Jan 15 04:06:00 CST 2015, time=2015-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033806, encodeId=f1a1203380632, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue May 05 21:06:00 CST 2015, time=2015-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281176, encodeId=64d212811e63f, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365600, encodeId=143a1365600eb, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Sat Jun 28 05:06:00 CST 2014, time=2014-06-28, status=1, ipAttribution=)]
    2014-06-28 cooco

相关资讯

BMJ:营养补充改善艾滋者健康状况

在非洲大约生活着2500万HIV感染者,其中大部分人都已经开始进行抗逆转录病毒疗法(ART)治疗疾病了;ART 可以明显减少个体AIDS 相关的死亡数。近日,刊登在国际杂志BMJ上的一篇研究论文中,来自哥本哈根大学的研究人员通过研究表示,在患者进行ART疗法的前三个月时每日的营养补充对于改善HIV患者的健康状况非常关键。 研究者Mette Frahm 

Nature:HIV研究遭遇非洲之困

4月12日,一个周六的早晨,10名警察突击搜查了Maaygo—— 一家位于肯尼亚西部基苏木市住宅区的研究男性健康和HIV(艾滋病病毒)/AIDS(艾滋病)的组织。员工眼睁睁地看着警察没收了传单甚至在避孕套使用方法示范中使用的阴茎模型。警察逮捕了该组织的负责人和财务主管以及一名成员,理由是“非法从事有关性取向方面的职业”。 当地同性恋权利保护组织负责人Daniel Onyango赶到警局解释,传

EASL 2014:MK-5172和MK-8742可有效治疗HCV1型和HIV共感染者

MK-5172是HCV NS3/4蛋白酶抑制剂。MK-8742是HCV NS5A抑制剂。来自巴塞罗那的研究人员发现,MK-5172和MK-8742+/-利巴韦林(RBV)可用于治疗HCV1型和HIV共感染患者。据悉,这是第一份HCV和HIV共感染患者服用口服药物治疗的报道。 该研究人群为丙肝初治、非肝硬化合并HIV感染的患者。患者正在进行稳定的抗逆转录病毒疗法(罗特格韦+替诺福韦或阿巴卡韦)。患

PLoS Med:超龄儿童艾滋病检测遇到的麻烦

近日,刊登在国际杂志PLoS Medicine上的一项研究中,来自伦敦城市学校卫生与热带医学院的研究人员通过研究表示,对少儿隐私和监护的关心会阻碍诊所对儿童HIV的检测。该研究结果对于如何提高对弱势群体的照顾提供了一些非常重要的信息。全球有超过三百万的儿童感染了艾滋病(90%在撒哈拉以南的非洲地区),2011年每天约有1000名儿童感染艾滋病。大龄儿童通常不知道艾滋病毒是在婴儿出生时通过母婴途径传

Nature:HIV试验遭受抨击

批评家们针对允许孕妇接受低于其所在国家标准的治疗方法的伦理学问题提出了质疑。 由于HIV病毒感染者的治疗方法突飞猛进,一些医生和激进主义分子强烈要求美国国立过敏症和传染病研究所(National Institute of Allergy and Infectious Diseases, NIAID)停止一项对比性试验,不要再比较新老疗法阻断HIV病毒母婴传播的效果了。 促进各地母婴生存(Pro

AIDS:研究发现HIV患者CD4细胞计数与缺血性卒中风险有关

一项为期15年的研究结果显示,HIV阳性的个体缺血性卒中的风险增高40%,但若此类个体CD4细胞计数增高,则相应风险与HIV阴性个体相似。相关研究最近发表于国际AIDS学会官方杂志AIDS上。这项研究由1996年开始至2011年结束,涉及仅2.5万HIV阳性个体。缺血性卒中的发生是由于血管内斑块形成所致,可导致血管狭窄或堵塞,阻断脑部的血液和氧气供应。CD4细胞计数低于500提示对抗感染和炎症反应

Baidu
map
Baidu
map
Baidu
map